SLC22A18

Across TCGA pan-cancer cohorts, SLC22A18 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC22A18 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC22A18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A18 expression acts as an unfavorable survival marker.

STAD, ESCA, and SKCM are the cancer types where SLC22A18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	9	view →
LIHC	OS	Median	III,IV	0.118	0.615	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	OS	Median	All	0.281	0.745	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC22A18–STAD (OS)

Open the STAD breakdown →